Fig. 2From: Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studiesPercentage of patients with reduction of ≥ 1 MHD frequency category in A) PROMISE-1 and B) PROMISE-2. MHDs, monthly headache daysBack to article page